Oct. 27 at 10:52 AM
$SRPT In Roche's
$ROG half-year 2025 earnings announcement, it was stated that Elevidys sales reached CHF 117 million for the period from January 1 to June 30, 2025.
🟢 Sales from the beginning of the year to the end of September = CHF 221 million in the Q3 announcement.
So, the sales growth rate for Elevidys for
$SRPT is 89%.
Amazingly, Q3 sales reached CHF 104 million.